Provided by Tiger Trade Technology Pte. Ltd.

Agenus

7.71
+0.16502.19%
Volume:532.65K
Turnover:4.03M
Market Cap:346.88M
PE:3.08
High:7.79
Open:7.52
Low:7.38
Close:7.54
52wk High:10.31
52wk Low:2.71
Shares:45.02M
Float Shares:40.38M
Volume Ratio:0.47
T/O Rate:1.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.50
EPS(LYR):-0.0034
ROE:-1278.83%
ROA:12.53%
PB:-1.74
PE(LYR):-2,268.85

Loading ...

Agenus Joins Chardan Annual Healthcare Investor Conference Fireside Chat

Reuters
·
19 mins ago

Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination

MT Newswires Live
·
Oct 08

Armenia Grants First Marketing Authorizations for Agenus’ BOT+Bal in Previously Treated Mss Metastatic Colorectal Cancer

THOMSON REUTERS
·
Oct 08

Agenus announces 3-year follow-up results from Phase 1b C-800-01 trial

TIPRANKS
·
Oct 05

Agenus Reports 48% Estimated Three-Year Survival in Recurrent Ovarian Cancer Trial of Botensilimab Plus Balstilimab

Reuters
·
Oct 03

Agenus Reports 48% Estimated Three-Year Survival with BOT+Bal in Recurrent Ovarian Cancer at Igcs 2026

THOMSON REUTERS
·
Oct 03

Agenus Presents Long-Term Survival Data for Botensilimab-Balstilimab in MSS Metastatic Colorectal Cancer at SITC 2026

Reuters
·
Oct 02

Agenus Shares Rise After Chardan Initiates Coverage at Buy

MT Newswires Live
·
Sep 29

Agenus Initiated at Buy by Rodman & Renshaw

Dow Jones
·
Sep 28

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 22

Chardan Initiates Agenus at Buy With $40 Price Target

MT Newswires Live
·
Sep 18

Agenus initiated with a Buy at Chardan

TIPRANKS
·
Sep 18

Agenus Director Marco Tullio Marcucci Files Initial Beneficial Ownership Statement

Reuters
·
Sep 16

Agenus files to sell 221,525 shares of common stock for holders

TIPRANKS
·
Sep 12

Agenus to Present 3-Year Survival Data for Botensilimab-Balstilimab Ovarian Cancer Study at IGCS 2026

Reuters
·
Sep 10

Agenus Releases Corporate Overview Presentation on Botensilimab-Balstilimab Neoadjuvant Colon Cancer Data

Reuters
·
Sep 03

Agenus Joins Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Aug 31

Agenus Reports 21.2-Month Median Survival in Phase 1b Bot+bal Study for MSS Metastatic Colorectal Cancer

Reuters
·
Aug 28

Agenus: No colorectal cancer recurrences observed at updated follow-up in trial

TIPRANKS
·
Aug 26

Agenus Reports no Recurrences in Phase 2 NEST Trial of Botensilimab Plus Balstilimab in Resectable Colon Cancer

Reuters
·
Aug 26